Sipuleucel-T is an autologous active cellular immunotherapy product engineered to induce a T-cell response against prostatic acid phosphatase (PAP), an antigen expressed in a majority of prostate cancer [4,5,6,7]. The gene discussed is ACP3; the disease is Familial prostate cancer.